Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bristol-Myers Squibb Co (NYSE:BMY)

59.63
Delayed Data
As of Feb 05
 -0.07 / -0.12%
Today’s Change
51.82
Today|||52-Week Range
70.87
-13.32%
Year-to-Date
String of Q4 Earnings Beat Fails to Revive Pharma ETFs
Feb 05 / Zacks.com
Bristol-Myers' Daklinza-Sovaldi Label Expanded in the EU
Jan 29 / Zacks.com
Why Achillion Pharmaceuticals Shares Crashed 37% in January
Feb 04 / MotleyFool.com
Bristol-Myers Beats on Q4 Earnings, Provides 2016 Guidance
Jan 28 / Zacks.com
Hedge fund pioneer is force behind hotly tipped biotech companies
Feb 04 / FT.com
Bristol-Myers (BMY) Beats on Q4 Earnings and Revenues
Jan 28 / Zacks.com
Why Medivation, Inc. Shares Crashed 32% in January
Feb 03 / MotleyFool.com
Why Bristol-Myers Squibb (BMY) Might Surprise This Earnings Season
Jan 27 / Zacks.com
Emotional Investing Deflates Exelixis, Inc. in January
Feb 02 / MotleyFool.com
Celgene Reveals Data on Second-Line Abraxane-Gemzar
Jan 25 / Zacks.com
3 Numbers That Matter When Merck Reports Its Fourth-Quarter Results
Feb 01 / MotleyFool.com
Will Bristol-Myers (BMY) Beat Q4 Earnings Expectations?
Jan 25 / Zacks.com
Investor calls for big pharma to slim down grow louder
Feb 01 / FT.com
Bristol-Myers' Opdivo/Yervoy Combination Expanded in U.S.
Jan 25 / Zacks.com
Will 2016 Be Merck & Co. Inc.'s Best Year Yet?
Feb 01 / MotleyFool.com
NHS approves B#5,700-a-month skin cancer drug
Jan 22 / FT.com
Analysts' Actions -- Bristol-Myers, Chipotle, Monster Beverage, Vertex Pharmaceutical...
Feb 01 / TheStreet.com
Big pharma joins forces to tackle cancer
Jan 11 / FT.com
Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question
Feb 01 / TheStreet.com
Sanofi unveils b,1.2bn of deals as part of push into cancer drugs
Jan 11 / FT.com
Gilead risks becoming victim of its own success
Jan 31 / FT.com